Globus Medical Long Term Debt 2010-2022 | GMED

Globus Medical long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Globus Medical long term debt for the quarter ending December 31, 2022 was $M, a NAN% increase year-over-year.
  • Globus Medical long term debt for 2022 was $0B, a NAN% decline from 2021.
  • Globus Medical long term debt for 2021 was $0B, a NAN% decline from 2020.
  • Globus Medical long term debt for 2020 was $0B, a NAN% decline from 2019.
Globus Medical Annual Long Term Debt
(Millions of US $)
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Globus Medical Quarterly Long Term Debt
(Millions of US $)
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $5.255B $0.759B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $212.206B 23.69
Edwards Lifesciences (EW) United States $49.143B 32.69
Alcon (ALC) Switzerland $32.311B 29.57
STERIS (STE) Ireland $17.996B 22.80
Fresenius Medical Care AG KGaA (FMS) Germany $11.408B 11.93
Teleflex (TFX) United States $11.141B 18.17
Penumbra (PEN) United States $10.162B 1565.71
Integer Holdings (ITGR) United States $2.448B 18.98
Glaukos (GKOS) United States $2.324B 0.00
Paragon 28 (FNA) United States $1.527B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.330B 17.30
Nevro (NVRO) United States $1.089B 0.00
Artivion (AORT) United States $0.488B 240.60